Suppression of Graft-Versus-Host Reactivity by a Single Host-Specific Blood Transfusion to Prospective Donors of Hemopoietic Cells

Knulst, André C.; Bril-Bazuin, C.; Savelkoul, H.F.J.; Benner, R.

doi:10.1097/00007890-199109000-00030

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, white cells can produce cytokines and other factors that might play a role. However, in our studies on the suppression of anti-host DTH during GVHD we did not find evidence for the latter suggestion [2]. Irradiation of the blood did not abrogate its ability to improve the survival, which is in line with data reported by others [lo].…”

Section: Discussionsupporting

confidence: 89%

“…We were not able to show a dominant suppressive effect by spleen cells from transfused donors, as could earlier be demonstrated in the DTH model [2].This might be due to the large histocompatibility differences in the strain combinations used. In a similar model, Halle-Pannenko et al found enhanced survival in a minor histoincompatible strain combination after donor pretreatment with allogeneic spleen cells [12].…”

Section: Discussioncontrasting

confidence: 59%

See 1 more Smart Citation

Improved survival from potentially lethal graft‐vs.‐host disease by donor pretreatment with a recipient‐specific blood transfusion. II. Evidence for a principal role of the CD4⁺ T cell subset

et al. 1993

View full text Add to dashboard Cite

Pretreatment of prospective donors of hemopoietic cells with a single recipient-specific blood transfusion can significantly decrease the morbidity and mortality of potentially lethal graft-vs.-host disease (GVHD) in lethally irradiated, allogeneically reconstituted mice. In a previous report we described the requirements for induction of this blood transfusion effect. In the present study we addressed in particular the mechanism underlying this effect. The beneficial effect of blood transfusion appeared to be due to the white blood cell population in the transfused blood. X-irradiation (20 Gy) of the blood prior to transfusion did not abrogate the effect, which makes a veto cell mechanism unlikely. The blood transfusion effect in this model appeared to be mediated by the CD4+ T cell subset, since purified CD4+ spleen cells from transfused donors caused considerably less morbidity and mortality than naive CD4+ spleen cells. Apparently CD8+ cells were not involved, because their absence did not affect the beneficial effect. This observation was further confirmed by the finding that treatment of recipient mice that were reconstituted with spleen cells from transfused donors with anti-CD8 monoclonal antibody (mAb) did not abrogate the blood transfusion effect. Interestingly, the blood transfusion effect was enhanced by administration of anti-CD4 mAb to the recipients. The anti-CD4 mAb might impair the interaction between T cells and antigen-presenting cells, resulting in functional inactivation.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussioncontrasting

confidence: 59%

Improved survival from potentially lethal graft‐vs.‐host disease by donor pretreatment with a recipient‐specific blood transfusion. II. Evidence for a principal role of the CD4⁺ T cell subset

et al. 1993

View full text Add to dashboard Cite

show abstract

Improved survival from potentially lethal graft‐vs.‐host disease by donor pretreatment with a recipient‐specific blood transfusion. I. Requirements for induction and specificity of the effect

et al. 1992

View full text Add to dashboard Cite

Pretreatment of prospective donors of hemopoietic cells with a single recipient-specific blood transfusion can significantly decrease the morbidity and mortality of graft-vs.-host disease (GVHD) in lethally irradiated, allogeneically reconstituted mice. This beneficial effect of donor pretreatment could be demonstrated in donor-recipient strain combinations that were H-2 + non-H-2, H-2, or only class II-disparate, but not in the class I-disparate C57BL-B6.C-H-2bm1 strain combination. The effect was proportional to the amount of recipient-strain blood used for transfusion. Donor transfusion with a single dose of 1 ml recipient-specific whole blood resulted in minimum GVHD, lower doses being less or not effective. The interval between donor pretreatment and the use of their hemopoietic cells for reconstitution appeared to be important. The best survival was found at an interval of 4 days. Multiple transfusion was not more effective than a single one. We compared the effectiveness of whole blood and irradiated spleen cells for donor pretreatment. Both protocols have been shown previously to suppress anti-recipient delayed-type hypersensitivity. It appeared that the blood transfusion protocol was superior to the spleen cell protocol. The beneficial effect appeared to be recipient specific, since a third-party blood transfusion did not improve GVHD. We found that the beneficial effect of donor blood transfusion was due to suppression of the anti-host immune response. The donor blood transfusion was able to induce bystander suppression to alloantigens that were not used for the induction of suppression, provided they were co-expressed with the specific alloantigens by the recipients. This also indicates that, although the induction of suppression is specific, the ultimate suppressive effect is non-specific.

show abstract

The Role of Blood Component Therapy in the Management of Canine and Feline Patients with Cancer

Rudloff¹

1995

Veterinary Clinics of North America: Small Animal Practice

View full text Add to dashboard Cite

Suppression of Graft-Versus-Host Reactivity by a Single Host-Specific Blood Transfusion to Prospective Donors of Hemopoietic Cells

Cited by 4 publications

References 0 publications

Improved survival from potentially lethal graft‐vs.‐host disease by donor pretreatment with a recipient‐specific blood transfusion. II. Evidence for a principal role of the CD4⁺ T cell subset

Improved survival from potentially lethal graft‐vs.‐host disease by donor pretreatment with a recipient‐specific blood transfusion. II. Evidence for a principal role of the CD4⁺ T cell subset

Improved survival from potentially lethal graft‐vs.‐host disease by donor pretreatment with a recipient‐specific blood transfusion. I. Requirements for induction and specificity of the effect

The Role of Blood Component Therapy in the Management of Canine and Feline Patients with Cancer

Contact Info

Product

Resources

About

Suppression of Graft-Versus-Host Reactivity by a Single Host-Specific Blood Transfusion to Prospective Donors of Hemopoietic Cells

Cited by 4 publications

References 0 publications

Improved survival from potentially lethal graft‐vs.‐host disease by donor pretreatment with a recipient‐specific blood transfusion. II. Evidence for a principal role of the CD4+ T cell subset

Improved survival from potentially lethal graft‐vs.‐host disease by donor pretreatment with a recipient‐specific blood transfusion. II. Evidence for a principal role of the CD4+ T cell subset

Improved survival from potentially lethal graft‐vs.‐host disease by donor pretreatment with a recipient‐specific blood transfusion. I. Requirements for induction and specificity of the effect

The Role of Blood Component Therapy in the Management of Canine and Feline Patients with Cancer

Contact Info

Product

Resources

About

Improved survival from potentially lethal graft‐vs.‐host disease by donor pretreatment with a recipient‐specific blood transfusion. II. Evidence for a principal role of the CD4⁺ T cell subset

Improved survival from potentially lethal graft‐vs.‐host disease by donor pretreatment with a recipient‐specific blood transfusion. II. Evidence for a principal role of the CD4⁺ T cell subset